BR112020017661A2 - Composição oftálmica compreendendo diquafosol e polímero catiônico - Google Patents

Composição oftálmica compreendendo diquafosol e polímero catiônico Download PDF

Info

Publication number
BR112020017661A2
BR112020017661A2 BR112020017661-3A BR112020017661A BR112020017661A2 BR 112020017661 A2 BR112020017661 A2 BR 112020017661A2 BR 112020017661 A BR112020017661 A BR 112020017661A BR 112020017661 A2 BR112020017661 A2 BR 112020017661A2
Authority
BR
Brazil
Prior art keywords
ophthalmic composition
cationic
composition according
diquafosol
ophthalmic
Prior art date
Application number
BR112020017661-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Kyohei Takahashi
Hiroyuki Asada
Asuka KAMIMURA
Kenji Morishima
Yusuke MOMOKAWA
Kenichi Endo
Original Assignee
Santen Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co., Ltd. filed Critical Santen Pharmaceutical Co., Ltd.
Publication of BR112020017661A2 publication Critical patent/BR112020017661A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
BR112020017661-3A 2018-02-28 2019-02-27 Composição oftálmica compreendendo diquafosol e polímero catiônico BR112020017661A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018035578 2018-02-28
JP2018-035578 2018-02-28
PCT/JP2019/007542 WO2019168023A1 (ja) 2018-02-28 2019-02-27 ジクアホソルおよびカチオン性ポリマーを含有する眼科用組成物

Publications (1)

Publication Number Publication Date
BR112020017661A2 true BR112020017661A2 (pt) 2020-12-22

Family

ID=67806273

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020017661-3A BR112020017661A2 (pt) 2018-02-28 2019-02-27 Composição oftálmica compreendendo diquafosol e polímero catiônico

Country Status (14)

Country Link
US (1) US20210000844A1 (https=)
EP (1) EP3760207A4 (https=)
JP (5) JP6716800B2 (https=)
KR (3) KR102796051B1 (https=)
CN (2) CN117137866A (https=)
BR (1) BR112020017661A2 (https=)
CA (1) CA3091700A1 (https=)
EA (1) EA202092030A1 (https=)
MX (2) MX2020008925A (https=)
PH (1) PH12020551313B1 (https=)
SG (1) SG11202007977RA (https=)
TW (4) TWI898399B (https=)
UA (1) UA129517C2 (https=)
WO (1) WO2019168023A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117137866A (zh) * 2018-02-28 2023-12-01 参天制药株式会社 含有地夸磷索及阳离子性聚合物的眼科用组合物
ES2994624T3 (en) * 2019-02-27 2025-01-27 Santen Pharmaceutical Co Ltd Ophthalmic composition containing diquafosol or salt thereof, vinyl-based polymer and cellulose-based polymer
JP6966667B2 (ja) * 2019-08-27 2021-11-17 参天製薬株式会社 ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物
KR102365008B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
JP7230169B2 (ja) * 2020-12-25 2023-02-28 参天製薬株式会社 ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液
CN113712910A (zh) * 2021-08-05 2021-11-30 广州市桐晖药业有限公司 一种滴眼液及其制备方法
JPWO2023054669A1 (https=) * 2021-09-30 2023-04-06
KR102794468B1 (ko) 2022-04-04 2025-04-14 서울대학교산학협력단 감미 억제용 조성물 및 식품의 감미 억제 방법
KR20250038935A (ko) * 2023-09-13 2025-03-20 루다큐어 주식회사 8-옥소-2'-데옥시구아노신 또는 이의 약학적으로 허용가능한 염을 포함하는 수용액 형태의 점안제
KR20250160050A (ko) 2024-05-03 2025-11-11 삼천당제약주식회사 물리화학적 특성이 개선된 안구건조증 예방 또는 치료용 약학 조성물
CN119970633A (zh) * 2025-03-26 2025-05-13 苏州乐珠制药有限公司 一种地夸磷索钠滴眼液及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01294620A (ja) 1988-05-19 1989-11-28 Kissei Pharmaceut Co Ltd 水溶液製剤およびその製造方法
US5358706A (en) * 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
JP3155689B2 (ja) * 1995-08-10 2001-04-16 昭和薬品化工株式会社 消炎点眼剤
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
WO1999005155A2 (en) 1997-07-25 1999-02-04 Inspire Pharmaceuticals, Inc. Salts of di(uridine 5'-tetraphosphate), method for preparation and uses thereof
JP2001294620A (ja) 2000-04-11 2001-10-23 Showa Denko Kk プラスチックレンズ材料、該材料の製造方法、プラスチックレンズ用組成物、該組成物を硬化してなるプラスチックレンズ、及び該プラスチックレンズの製造方法
AU2001260643B9 (en) * 2000-05-30 2006-10-19 Merck Sharp & Dohme Corp. Ectocornea extension promoters
KR20070114130A (ko) * 2005-02-14 2007-11-29 존슨 앤드 존슨 비젼 케어, 인코포레이티드 착용감이 편안한 안용 장치 및 이의 제조방법
JP4515960B2 (ja) 2005-05-19 2010-08-04 株式会社資生堂 整髪料洗浄剤及びその使用方法
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
JP5421272B2 (ja) * 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 眼病治療のための組成物及び方法
BRPI0909797A2 (pt) * 2008-03-07 2017-08-22 Sun Pharma Advanced Res Co Ltd Composição oftálmica
UA113839C2 (xx) * 2010-12-28 2017-03-27 Очний розчин, який містить диквафозол, спосіб його отримання і спосіб інгібування утворення нерозчинного осаду
KR101536885B1 (ko) * 2012-03-26 2015-07-14 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 함유 점안액
EP3139903B1 (en) * 2014-05-07 2019-07-03 Croma-Pharma Gesellschaft m.b.H. Aqueous ophthalmic solution and method for treating dry eye syndrome
WO2015190483A1 (ja) * 2014-06-10 2015-12-17 ロート製薬株式会社 眼科用水性組成物
KR102330736B1 (ko) * 2014-12-25 2021-11-23 산텐 세이야꾸 가부시키가이샤 수성 점안액
KR101587385B1 (ko) * 2015-07-29 2016-01-21 국제약품공업주식회사 사이클로스포린 함유 무자극성의 안약조성물 및 편리한 제조방법
WO2017033967A1 (ja) * 2015-08-24 2017-03-02 参天製薬株式会社 眼科用フィルム製剤
PT3266446T (pt) * 2016-07-07 2019-01-30 Salvat Lab Sa Composição oftálmica compreendendo óleo de rícino e triglicérido de cadeia média
CN106772747B (zh) * 2016-12-26 2022-10-18 深圳市光科全息技术有限公司 一种光学膜及其制作方法
RU2710366C1 (ru) * 2017-04-25 2019-12-26 Вакамото Фармасьютикал Ко., Лтд. Термочувствительная гелеобразующая искусственная слеза
JP6582029B2 (ja) * 2017-10-03 2019-09-25 株式会社メニコン 眼科用組成液及びその使用方法
CN117137866A (zh) * 2018-02-28 2023-12-01 参天制药株式会社 含有地夸磷索及阳离子性聚合物的眼科用组合物
CN108853016A (zh) * 2018-09-26 2018-11-23 广州大光制药有限公司 一种地夸磷索钠滴眼液及其制备方法
ES2994624T3 (en) * 2019-02-27 2025-01-27 Santen Pharmaceutical Co Ltd Ophthalmic composition containing diquafosol or salt thereof, vinyl-based polymer and cellulose-based polymer
JP6966667B2 (ja) 2019-08-27 2021-11-17 参天製薬株式会社 ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物

Also Published As

Publication number Publication date
KR20250053220A (ko) 2025-04-21
SG11202007977RA (en) 2020-09-29
CN111757742A (zh) 2020-10-09
MX2022014791A (es) 2023-01-16
JP6716800B2 (ja) 2020-07-01
PH12020551313A1 (en) 2021-09-06
EA202092030A1 (ru) 2020-11-16
US20210000844A1 (en) 2021-01-07
TW202306572A (zh) 2023-02-16
JP2020138980A (ja) 2020-09-03
TWI898399B (zh) 2025-09-21
JP7796782B2 (ja) 2026-01-09
EP3760207A4 (en) 2023-10-04
JP2024045506A (ja) 2024-04-02
KR102472773B1 (ko) 2022-11-30
KR102796051B1 (ko) 2025-04-14
KR20220163519A (ko) 2022-12-09
UA129517C2 (uk) 2025-05-21
JP7472202B2 (ja) 2024-04-22
CN117137866A (zh) 2023-12-01
TWI833406B (zh) 2024-02-21
TWI781296B (zh) 2022-10-21
CN111757742B (zh) 2023-09-26
CA3091700A1 (en) 2019-09-06
MX2020008925A (es) 2020-10-01
PH12020551313B1 (en) 2024-02-28
JP2026034664A (ja) 2026-02-27
TW202000212A (zh) 2020-01-01
TW202600146A (zh) 2026-01-01
JPWO2019168023A1 (ja) 2020-05-28
TW202423451A (zh) 2024-06-16
EP3760207A1 (en) 2021-01-06
JP2022136152A (ja) 2022-09-15
WO2019168023A1 (ja) 2019-09-06
KR20200127002A (ko) 2020-11-09
JP7297718B2 (ja) 2023-06-26

Similar Documents

Publication Publication Date Title
BR112020017661A2 (pt) Composição oftálmica compreendendo diquafosol e polímero catiônico
TWI848171B (zh) 含有迪夸弗索(diquafosol)或其鹽、及聚乙烯吡咯烷酮之水性眼科用組合物
ES2994624T3 (en) Ophthalmic composition containing diquafosol or salt thereof, vinyl-based polymer and cellulose-based polymer
HK40035045A (en) Ophthalmic composition comprising diquafosol and cationic polymer
EA044372B1 (ru) Офтальмологическая композиция, включающая диквафозол и катионный полимер
HK40037570B (zh) 含有地夸磷索及阳离子性聚合物的眼科用组合物
HK40037570A (en) Ophthalmic composition comprising diquafosol and cationic polymer

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2868 DE 23-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.